<code id='7C6212F08D'></code><style id='7C6212F08D'></style>
    • <acronym id='7C6212F08D'></acronym>
      <center id='7C6212F08D'><center id='7C6212F08D'><tfoot id='7C6212F08D'></tfoot></center><abbr id='7C6212F08D'><dir id='7C6212F08D'><tfoot id='7C6212F08D'></tfoot><noframes id='7C6212F08D'>

    • <optgroup id='7C6212F08D'><strike id='7C6212F08D'><sup id='7C6212F08D'></sup></strike><code id='7C6212F08D'></code></optgroup>
        1. <b id='7C6212F08D'><label id='7C6212F08D'><select id='7C6212F08D'><dt id='7C6212F08D'><span id='7C6212F08D'></span></dt></select></label></b><u id='7C6212F08D'></u>
          <i id='7C6212F08D'><strike id='7C6212F08D'><tt id='7C6212F08D'><pre id='7C6212F08D'></pre></tt></strike></i>

          entertainment

          entertainment

          author:explore    Page View:742
          Photo illustration of a person holding smartphone with website of company Welsh, Carson Anderson and Stowe (WCAS) on screen with logo
          Physician groups backed by Welsh, Carson, Anderson & Stowe are looking to influence federal merger policy. Adobe

          Three large and growing physician groups backed by the private equity giant Welsh, Carson, Anderson & Stowe have hired a prominent lobbying firm to influence federal policy covering mergers and acquisitions.

          Over the past two weeks, United Musculoskeletal Partners, U.S. Anesthesia Partners, and U.S. Radiology Specialists each registered with Forbes Tate Partners, a lobbying shop founded by political insiders who used to work in President Bill Clinton’s administration.

          advertisement

          The doctor groups hired Forbes Tate to lobby on “issues related to health care consolidation,” according to federal lobbying disclosures. Each company and Welsh Carson did not respond to inquiries. Forbes Tate also did not respond.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Eli Lilly to pay $200M for Beam’s stake in gene
          Eli Lilly to pay $200M for Beam’s stake in gene

          AdobeEliLillysaidTuesdaythatitwillpay$200milliontogene-editingfirmBeamTherapeuticsforBeam’sstakeinVe

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Readout Newsletter: What happened with Sarepta's Duchenne data

          AndrewHarnik/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnews